Who makes Candesartan plus Metformin?

Candesartan plus Metformin is developed by Third Military Medical University.

What development phase is Candesartan plus Metformin in?

Candesartan plus Metformin is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Candesartan plus Metformin

Third Military Medical University · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Candesartan plus Metformin
Sponsor	Third Military Medical University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Candesartan plus Metformin CI brief — competitive landscape report
Candesartan plus Metformin updates RSS · CI watch RSS
Third Military Medical University portfolio CI